Maria Parasyri1, Per Brandström1,2, Johanna Uusimaa3,4, Elsebet Ostergaard5, Omar Hikmat6,7, Pirjo Isohanni8,9, Karin Naess10, I F M de Coo11, Andrés Nascimento Osorio12, Matti Nuutinen3,4, Christopher Lindberg13, Laurence A Bindoff7,14, Már Tulinius1,2, Niklas Darin1,2, Kalliopi Sofou1,2. 1. Department of Paediatrics, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden. 2. Department of Paediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 3. Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland. 4. PEDEGO Research Unit, Research Unit for Pediatrics, Pediatric Neurology, Pediatric Surgery, Child Psychiatry, Dermatology, Clinical Genetics, Obstetrics and Gynecology, Ophthalmology, Otorhinolaryngology, Medical Research Center Oulu (MRC Oulu), University of Oulu, Oulu, Finland. 5. Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 6. Department of Pediatrics and Adolescent Medicine, Haukeland University Hospital, Bergen, Norway. 7. Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway. 8. Department of Pediatric Neurology, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 9. Research Programs Unit, Stem Cells and Metabolism, University of Helsinki, Helsinki, Finland. 10. Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden. 11. Department Toxicogenomics, Faculty of Health, Medicine and Life Sciences, Graduate School MHeNS, Maastricht University, Maastricht, The Netherlands. 12. Neuromuscular Diseases Unit, Hospital Sant Joan de Déu, Barcelona, Spain. 13. Department of Neurology, Neuromuscular Centre, Sahlgrenska University Hospital, Gothenburg, Sweden. 14. Neuro-SysMed, Center of Excellence for Clinical Research in Neurological Diseases, Haukeland University Hospital, Bergen, Norway.
Abstract
Aims: This study aimed to investigate associations between renal and extrarenal manifestations of mitochondrial diseases and their natural history as well as predictors of renal disease severity and overall disease outcome. The secondary aim was to generate a protocol of presymptomatic assessment and monitoring of renal function in patients with a defined mitochondrial disease. Methods: A multicenter, retrospective cohort study was performed by the Mitochondrial Clinical and Research Network (MCRN). Patients of any age with renal manifestations associated with a genetically verified mitochondrial disease were included from 8 expert European centers specializing in mitochondrial diseases: Gothenburg, Oulu, Copenhagen, Bergen, Helsinki, Stockholm, Rotterdam, and Barcelona. Results: Of the 36 patients included, two-thirds had mitochondrial DNA-associated disease. Renal manifestations were the first sign of mitochondrial disease in 19%, and renal involvement was first identified by laboratory tests in 57% of patients. Acute kidney injury occurred in 19% of patients and was the first sign of renal disease in the majority of these. The most common renal manifestation was chronic kidney disease (75% with stage 2 or greater), followed by tubulopathy (44.4%), the latter seen mostly among patients with single large-scale mitochondrial DNA deletions. Acute kidney injury and tubulopathy correlated with worse survival outcome. The most common findings on renal imaging were increased echogenicity and renal dysplasia/hypoplasia. Renal histology revealed focal segmental glomerulosclerosis, nephrocalcinosis, and nephronophthisis. Conclusion: Acute kidney injury is a distinct renal phenotype in patients with mitochondrial disease. Our results highlight the importance to recognize renal disease as a sign of an underlying mitochondrial disease. Acute kidney injury and tubulopathy are 2 distinct indicators of poor survival in patients with mitochondrial diseases.
Aims: This study aimed to investigate associations between renal and extrarenal manifestations of mitochondrial diseases and their natural history as well as predictors of renal disease severity and overall disease outcome. The secondary aim was to generate a protocol of presymptomatic assessment and monitoring of renal function in patients with a defined mitochondrial disease. Methods: A multicenter, retrospective cohort study was performed by the Mitochondrial Clinical and Research Network (MCRN). Patients of any age with renal manifestations associated with a genetically verified mitochondrial disease were included from 8 expert European centers specializing in mitochondrial diseases: Gothenburg, Oulu, Copenhagen, Bergen, Helsinki, Stockholm, Rotterdam, and Barcelona. Results: Of the 36 patients included, two-thirds had mitochondrial DNA-associated disease. Renal manifestations were the first sign of mitochondrial disease in 19%, and renal involvement was first identified by laboratory tests in 57% of patients. Acute kidney injury occurred in 19% of patients and was the first sign of renal disease in the majority of these. The most common renal manifestation was chronic kidney disease (75% with stage 2 or greater), followed by tubulopathy (44.4%), the latter seen mostly among patients with single large-scale mitochondrial DNA deletions. Acute kidney injury and tubulopathy correlated with worse survival outcome. The most common findings on renal imaging were increased echogenicity and renal dysplasia/hypoplasia. Renal histology revealed focal segmental glomerulosclerosis, nephrocalcinosis, and nephronophthisis. Conclusion: Acute kidney injury is a distinct renal phenotype in patients with mitochondrial disease. Our results highlight the importance to recognize renal disease as a sign of an underlying mitochondrial disease. Acute kidney injury and tubulopathy are 2 distinct indicators of poor survival in patients with mitochondrial diseases.
Authors: Mei Tran; Denise Tam; Amit Bardia; Manoj Bhasin; Glenn C Rowe; Ajay Kher; Zsuzsanna K Zsengeller; M Reza Akhavan-Sharif; Eliyahu V Khankin; Magali Saintgeniez; Sascha David; Deborah Burstein; S Ananth Karumanchi; Isaac E Stillman; Zoltan Arany; Samir M Parikh Journal: J Clin Invest Date: 2011-09-01 Impact factor: 14.808
Authors: John F O'Toole; Yangjian Liu; Erica E Davis; Christopher J Westlake; Massimo Attanasio; Edgar A Otto; Dominik Seelow; Gudrun Nurnberg; Christian Becker; Matti Nuutinen; Mikko Kärppä; Jaakko Ignatius; Johanna Uusimaa; Salla Pakanen; Elisa Jaakkola; Lambertus P van den Heuvel; Henry Fehrenbach; Roger Wiggins; Meera Goyal; Weibin Zhou; Matthias T F Wolf; Eric Wise; Juliana Helou; Susan J Allen; Carlos A Murga-Zamalloa; Shazia Ashraf; Moumita Chaki; Saskia Heeringa; Gil Chernin; Bethan E Hoskins; Hassan Chaib; Joseph Gleeson; Takehiro Kusakabe; Takako Suzuki; R Elwyn Isaac; Lynne M Quarmby; Bryan Tennant; Hisashi Fujioka; Hannu Tuominen; Ilmo Hassinen; Hellevi Lohi; Judith L van Houten; Agnes Rotig; John A Sayer; Boris Rolinski; Peter Freisinger; Sethu M Madhavan; Martina Herzer; Florence Madignier; Holger Prokisch; Peter Nurnberg; Peter K Jackson; Peter Jackson; Hemant Khanna; Nicholas Katsanis; Friedhelm Hildebrandt Journal: J Clin Invest Date: 2010-02-22 Impact factor: 14.808
Authors: Richard E Neiberger; Jaime C George; Leigh Ann Perkins; Douglas W Theriaque; Alan D Hutson; Peter W Stacpoole Journal: Am J Kidney Dis Date: 2002-01 Impact factor: 8.860
Authors: Paula Pérez-Albert; Carmen de Lucas Collantes; Miguel Ángel Fernández-García; Teresa de Rojas; Cristina Aparicio López; Luis Gutiérrez-Solana Journal: JIMD Rep Date: 2017-12-17
Authors: Christoph Freyer; Henrik Stranneheim; Karin Naess; Arnaud Mourier; Andrea Felser; Camilla Maffezzini; Nicole Lesko; Helene Bruhn; Martin Engvall; Rolf Wibom; Michela Barbaro; Yvonne Hinze; Måns Magnusson; Robin Andeer; Rolf H Zetterström; Ulrika von Döbeln; Anna Wredenberg; Anna Wedell Journal: J Med Genet Date: 2015-06-17 Impact factor: 6.318
Authors: Larissa P Govers; Hakan R Toka; Ali Hariri; Stephen B Walsh; Detlef Bockenhauer Journal: Pediatr Nephrol Date: 2020-01-10 Impact factor: 3.714